CZP 400 mg (n=89) | |
Age, mean±SD, years | 30.2±9.9 |
BMI, mean±SD, kg/m2 | 22.1±3.6 |
Males, n (%) | 30 (34) |
CDEIS | |
Mean±SD | 14.5±5.3 |
Median | 13.3 |
IQR | 10.3–16.9 |
CDAI | |
Mean±SD | 297±75 |
Median | 290 |
IQR | 236–342 |
CRP, mg/l | |
Geometric mean (CV) | 19 (1.4) |
Median | 29 |
IQR | 9–46 |
Disease duration, years | |
Mean±SD | 7.9±7.9 |
Median | 6.5 |
Number of resections, n (%) | |
0 | 71 (80) |
1 | 11 (12) |
2 | 5 (6) |
3 | 2 (2) |
Prior anti-TNF therapy, n (%) | 2 (2) |
At least one concomitant medication potentially influencing CD, % patients | 79 |
Immunosuppressants | 51 |
Corticosteroids | 42 |
5-Aminosalicylic acid | 22 |
Antibiotics | 15 |
BMI, body mass index; CD, Chron's disease; CDAI, Crohn's Disease Activity Index; CDEIS, Crohn's Disease Endoscopic Index of Severity; CRP, C reactive protein; CV, coefficient of variation; CZP, certolizumab pegol; TNF, tumour necrosis factor.